A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 21 Oct 2019 Status changed from active, no longer recruiting to completed.
- 14 Aug 2019 This trial has been completed in Bulgaria as per EudraCT record(EudraCT2016-000498-19)
- 08 Jan 2019 Planned End Date changed from 12 Sep 2019 to 27 Jul 2019.